Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Rubius Therapeutics Inc (RUBY)

Rubius Therapeutics Inc (RUBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,024,645
  • Shares Outstanding, K 79,801
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,200 K
  • 60-Month Beta 2.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.60
  • Number of Estimates 5
  • High Estimate -0.41
  • Low Estimate -0.68
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -71.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.96 +84.48%
on 11/15/19
13.17 -2.51%
on 12/11/19
+1.89 (+17.26%)
since 11/11/19
3-Month
6.96 +84.48%
on 11/15/19
13.17 -2.51%
on 12/11/19
+3.05 (+31.15%)
since 09/11/19
52-Week
6.96 +84.48%
on 11/15/19
20.44 -37.20%
on 12/12/18
-5.92 (-31.56%)
since 12/11/18

Most Recent Stories

More News
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 3.54 (+1.29%)
DNLI : 19.00 (+4.97%)
EVLO : 4.39 (+4.77%)
KLDO : 5.31 (+3.11%)
MRNA : 18.65 (-1.17%)
RUBY : 12.84 (+6.82%)
MCRB : 4.09 (+2.00%)
SYRS : 4.63 (-2.94%)
Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported...

RUBY : 12.84 (+6.82%)
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced today...

RUBY : 12.84 (+6.82%)
Flagship Pioneering Appoints Prakash Raman, Ph.D. as Senior Partner and Chief Business Development Officer

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development...

NVS : 92.53 (-0.55%)
AXLA : 3.54 (+1.29%)
DNLI : 19.00 (+4.97%)
EVLO : 4.39 (+4.77%)
KLDO : 5.31 (+3.11%)
MRNA : 18.65 (-1.17%)
RUBY : 12.84 (+6.82%)
MCRB : 4.09 (+2.00%)
SYRS : 4.63 (-2.94%)
Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

RUBY : 12.84 (+6.82%)
Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

RUBY : 12.84 (+6.82%)
Rubius Therapeutics to Announce Third Quarter 2019 Financial Results

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

RUBY : 12.84 (+6.82%)
Entrada Therapeutics Appoints Nathan Dowden as Chief Operating Officer

Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced the appointment of Nathan...

RUBY : 12.84 (+6.82%)
Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

RUBY : 12.84 (+6.82%)
Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced...

MS : 49.25 (-0.40%)
RUBY : 12.84 (+6.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade RUBY with:

Business Summary

Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

2nd Resistance Point 13.82
1st Resistance Point 13.33
Last Price 12.84
1st Support Level 12.19
2nd Support Level 11.53

See More

52-Week High 20.44
Fibonacci 61.8% 15.29
Fibonacci 50% 13.70
Last Price 12.84
Fibonacci 38.2% 12.11
52-Week Low 6.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar